{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T22:44:24Z","timestamp":1794869064742,"version":"4.9.1"},"reference-count":66,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["MC"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec><jats:title>Aims:<\/jats:title><jats:p>The aim of the study was to search for new anticancer agents as TRKA inhibitors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Background:<\/jats:title><jats:p>A series of new salicylic acid hydrazide hydrazones were synthesized and evaluated for their in vitro anticancer activities against lung (A549), ovarian (SK-OV-3), skin (SK-MEL-2), and colon (HCT15) cancer cell lines, and tropomyosin receptor kinase A (TRKA) inhibitory activities.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective:<\/jats:title><jats:p>In this study, we focused on the synthesis and anticancer properties evaluation of salicylic acid hydrazide hydrazones as TRKA inhibitors. The in vitro anticancer activities of hydrazone analogs were measured against four cancer cell lines, and the TRKA inhibitory properties were investigated using an enzyme assay to determine their modes of action. In silico molecular docking was conducted using the crystal structure of the TRKA receptor to study the interactions and modes of binding at its active site, and ligand-based target predictions were used to identify putative secondary enzymatic targets of the synthesized compounds. Additionally, pharmacokinetic properties, toxicity effects, and drug scores of the studied molecules were also assessed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>A series of hydrazide hydrazones were prepared by means of a facile and straight-forward two-step reaction under soft reflux conditions from a methyl ester of substituted aromatic acids and hydrazine hydrate followed by the condensation with substituted aldehydes. In vitro cytotoxic properties of the synthesized compounds were screened against four human cancer cells using the SRB (sulforhodamine-B) colorimetric method. The TRKA inhibitory activity was measured by enzymatic assay. In silico ADME, drug score properties, docking studies, and ligand-based target prediction analyses were performed using Osiris Cheminformatics and AutoDock Vina, and SwissTargetPrediction bioinformatics software.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>In vitro bioassays revealed that compound 6 exhibited the most potent broad-spectrum anticancer activities with IC50 values of 0.144, &lt;0.001, 0.019, and 0.022 \u03bcM against A549, SK-OV-3, SK-MEL-2, and HCT15 cancer cells, respectively, followed by compounds 11, 3a, and 9. In TRKA inhibitory assays, compounds 3e and 11 demonstrated the highest potency with IC50 values of 111 and 614 nM, respectively. The results of docking studies on 3e and 11 with the active site of the TRKA receptor revealed that both compounds interacted as previously reported TRKA inhibitors with high docking scores.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>New salicylic acid hydrazide hydrazones were synthesized, and the most active compounds exhibited significant anticancer properties against A549, SK-OV-3, SK-MEL-2, and HCT15 cancer cells, suggesting to be good candidates for in vivo studies. The results obtained in the present study would help in the design and preparation of new hydrazidehydrazone analogs as potential TRKA inhibitors for cancer treatment.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1573406418666220427105041","type":"journal-article","created":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T07:37:11Z","timestamp":1651131431000},"page":"47-63","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Hydrazide-hydrazones as Small Molecule Tropomyosin Receptor Kina se A (TRKA) Inhibitors: Synthesis, Anticancer Activities, In silico ADME and Molecular Docking Studies"],"prefix":"10.2174","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8211-0067","authenticated-orcid":true,"given":"Mohammad Sayed","family":"Alam","sequence":"first","affiliation":[{"name":"Department of Chemistry, Jagannath University, Dhaka 1100, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5784-3653","authenticated-orcid":true,"given":"Dong-Ung","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Bioscience, Dongguk University, Gyeongju 780-714, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.4255\/mcpharmacol.09.05","volume":"1","author":"Rayburn E.R.","year":"2009","unstructured":"Rayburn E.R.; Ezell S.J.; Zhang R.; Anti-inflammatory agents for cancer therapy. Mol Cell Pharmacol 2009,1(1),29-43","journal-title":"Mol Cell Pharmacol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.ejmech.2012.06.003","volume":"54","author":"He J.","year":"2012","unstructured":"He J.; Wang X.; Zhao X.; Liang Y.; He H.; Fu L.; Synthesis and antitumor activity of novel quinazoline derivatives containing thiosemicarbazide moiety. Eur J Med Chem 2012,54,925-930","journal-title":"Eur J Med Chem"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"100325","DOI":"10.1016\/j.ctarc.2021.100325","volume":"27","author":"Swami U.","year":"2021","unstructured":"Swami U.; Grivas P.; Pal S.K.; Agarwal N.; Utilization of systemic therapy for treatment of advanced urothelial carcinoma: Lessons from real world experience. Cancer Treat Res Commun 2021,27,100325","journal-title":"Cancer Treat Res Commun"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1242\/dmm.030007","volume":"10","author":"Cagan R.","year":"2017","unstructured":"Cagan R.; Meyer P.; Rethinking cancer: Current challenges and opportunities in cancer research. Dis Model Mech 2017,10(4),349-352","journal-title":"Dis Model Mech"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1007\/s12035-007-0028-8","volume":"35","author":"Ren K.","year":"2007","unstructured":"Ren K.; Dubner R.; Pain facilitation and activity-dependent plasticity in pain modulatory circuitry: Role of BDNF-TrkB signaling and NMDA receptors. Mol Neurobiol 2007,35(3),224-235","journal-title":"Mol Neurobiol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1038\/nn.3237","volume":"15","author":"Lai K.O.","year":"2012","unstructured":"Lai K.O.; Wong A.S.; Cheung M.C.; Xu P.; Liang Z.; Lok K.C.; Xie H.; Palko M.E.; Yung W.H.; Tessarollo L.; Cheung Z.H.; Ip N.Y.; TrkB phosphorylation by Cdk5 is required for activity-dependent structural plasticity and spatial memory. Nat Neurosci 2012,15(11),1506-1515","journal-title":"Nat Neurosci"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1158\/2159-8290.CD-14-0765","volume":"5","author":"Vaishnavi A.","year":"2015","unstructured":"Vaishnavi A.; Le A.T.; Doebele R.C.; TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov 2015,5(1),25-34","journal-title":"Cancer Discov"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0092-8674(91)90419-Y","volume":"65","author":"Klein R.","year":"1991","unstructured":"Klein R.; Jing S.Q.; Nanduri V.; O\u2019Rourke E.; Barbacid M.; The trk proto-oncogene encodes a receptor for nerve growth factor. Cell 1991,65(1),189-197","journal-title":"Cell"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/0092-8674(91)90628-C","volume":"66","author":"Klein R.","year":"1991","unstructured":"Klein R.; Nanduri V.; Jing S.A.; Lamballe F.; Tapley P.; Bryant S.; Cordon-Cardo C.; Jones K.R.; Reichardt L.F.; Barbacid M.; The trkB tyrosine protein kinase is a receptor for brain-derived neurotrophic factor and neurotrophin-3. Cell 1991,66(2),395-403","journal-title":"Cell"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.1073\/pnas.89.7.3060","volume":"89","author":"Ip N.Y.","year":"1992","unstructured":"Ip N.Y.; Ib&#xE1;&#xF1;ez C.F.; Nye S.H.; McClain J.; Jones P.F.; Gies D.R.; Belluscio L.; Le Beau M.M.; Espinosa R.; Squinto S.P.; Mammalian neurotrophin-4: Structure, chromosomal localization, tissue distribution, and receptor specificity. Proc Natl Acad Sci USA 1992,89(7),3060-3064","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/0092-8674(91)90442-2","volume":"66","author":"Lamballe F.","year":"1991","unstructured":"Lamballe F.; Klein R.; Barbacid M.; trkC, a new member of the trk family of tyrosine protein kinases, is a receptor for neurotrophin-3. Cell 1991,66(5),967-979","journal-title":"Cell"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"523","DOI":"10.2174\/157015911798376208","volume":"9","author":"Siniscalco D.","year":"2011","unstructured":"Siniscalco D.; Giordano C.; Rossi F.; Maione S.; de Novellis V.; Role of neurotrophins in neuropathic pain. Curr Neuropharmacol 2011,9(4),523-529","journal-title":"Curr Neuropharmacol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"46","DOI":"10.2174\/187152708783885174","volume":"7","author":"Skaper S.D.","year":"2008","unstructured":"Skaper S.D.; The biology of neurotrophins, signalling pathways, and functional peptide mimetics of neurotrophins and their receptors. CNS Neurol Disord Drug Targets 2008,7(1),46-62","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"e000023","DOI":"10.1136\/esmoopen-2015-000023","volume":"1","author":"Amatu A.","year":"2016","unstructured":"Amatu A.; Sartore-Bianchi A.; Siena S.; NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open 2016,1(2),e000023","journal-title":"ESMO Open"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1093\/carcin\/bgq180","volume":"31","author":"Jin W.","year":"2010","unstructured":"Jin W.; Kim G.M.; Kim M.S.; Lim M.H.; Yun C.; Jeong J.; Nam J.S.; Kim S.J.; TrkC plays an essential role in breast tumor growth and metastasis. Carcinogenesis 2010,31(11),1939-1947","journal-title":"Carcinogenesis"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11864-020-00741-z","volume":"21","author":"Harada G.","year":"2020","unstructured":"Harada G.; Gongora A.B.L.; da Costa C.M.F.; Santini F.C.; TRK inhibitors in non-small cell lung cancer. Curr Treat Options Oncol 2020,21(5),39","journal-title":"Curr Treat Options Oncol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.molonc.2014.06.001","volume":"8","author":"Ardini E.","year":"2014","unstructured":"Ardini E.; Bosotti R.; Borgia A.L.; De Ponti C.; Somaschini A.; Cammarota R.; Amboldi N.; Raddrizzani L.; Milani A.; Magnaghi P.; Ballinari D.; Casero D.; Gasparri F.; Banfi P.; Avanzi N.; Saccardo M.B.; Alzani R.; Bandiera T.; Felder E.; Donati D.; Pesenti E.; Sartore-Bianchi A.; Gambacorta M.; Pierotti M.A.; Siena S.; Veronese S.; Galvani A.; Isacchi A.; The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition. Mol Oncol 2014,8(8),1495-1507","journal-title":"Mol Oncol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.mce.2009.10.009","volume":"321","author":"Greco A.","year":"2010","unstructured":"Greco A.; Miranda C.; Pierotti M.A.; Rearrangements of NTRK1 gene in papillary thyroid carcinoma. Mol Cell Endocrinol 2010,321(1),44-49","journal-title":"Mol Cell Endocrinol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1093\/annonc\/mdw042","volume":"27","author":"Drilon A.","year":"2016","unstructured":"Drilon A.; Li G.; Dogan S.; Gounder M.; Shen R.; Arcila M.; Wang L.; Hyman D.M.; Hechtman J.; Wei G.; Cam N.R.; Christiansen J.; Luo D.; Maneval E.C.; Bauer T.; Patel M.; Liu S.V.; Ou S.H.; Farago A.; Shaw A.; Shoemaker R.F.; Lim J.; Hornby Z.; Multani P.; Ladanyi M.; Berger M.; Katabi N.; Ghossein R.; Ho A.L.; What hides behind the MASC: Clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC). Ann Oncol 2016,27(5),920-926","journal-title":"Ann Oncol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/ng.2734","volume":"45","author":"Frattini V.","year":"2013","unstructured":"Frattini V.; Trifonov V.; Chan J.M.; Castano A.; Lia M.; Abate F.; Keir S.T.; Ji A.X.; Zoppoli P.; Niola F.; Danussi C.; Dolgalev I.; Porrati P.; Pellegatta S.; Heguy A.; Gupta G.; Pisapia D.J.; Canoll P.; Bruce J.N.; McLendon R.E.; Yan H.; Aldape K.; Finocchiaro G.; Mikkelsen T.; Priv&#xE9; G.G.; Bigner D.D.; Lasorella A.; Rabadan R.; Iavarone A.; The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet 2013,45(10),1141-1149","journal-title":"Nat Genet"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1177\/1947601911412376","volume":"2","author":"Gysin S.","year":"2011","unstructured":"Gysin S.; Salt M.; Young A.; McCormick F.; Therapeutic strategies for targeting ras proteins. Genes Cancer 2011,2(3),359-372","journal-title":"Genes Cancer"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1517\/13543776.2014.910195","volume":"24","author":"McCarthy C.","year":"2014","unstructured":"McCarthy C.; Walker E.; Tropomyosin receptor kinase inhibitors: A patent update 2009 - 2013. Expert Opin Ther Pat 2014,24(7),731-744","journal-title":"Expert Opin Ther Pat"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1021\/acs.jmedchem.8b01092","volume":"62","author":"Yan W.","year":"2019","unstructured":"Yan W.; Lakkaniga N.R.; Carlomagno F.; Santoro M.; McDonald N.Q.; Lv F.; Gunaganti N.; Frett B.; Li H.Y.; Insights into current tropomyosin receptor kinase (TRK) inhibitors: Development and clinical application. J Med Chem 2019,62(4),1731-1760","journal-title":"J Med Chem"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.apsb.2020.05.004","volume":"11","author":"Jiang T.","year":"2021","unstructured":"Jiang T.; Wang G.; Liu Y.; Feng L.; Wang M.; Liu J.; Chen Y.; Ouyang L.; Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers. Acta Pharm Sin B 2021,11(2),355-372","journal-title":"Acta Pharm Sin B"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"236","DOI":"10.5012\/jkcs.2012.56.2.236","volume":"56","author":"Bhole R.P.","year":"2012","unstructured":"Bhole R.P.; Borkar D.D.; Bhusari K.P.; Patil P.A.; Design and synthesis of p-hydroxybenzohydrazide derivatives for their antimycobacterial activity. J Korean Chem Soc 2012,56,236-245","journal-title":"J Korean Chem Soc"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.bmcl.2016.11.056","volume":"27","author":"Bhalerao M.B.","year":"2017","unstructured":"Bhalerao M.B.; Dhumal S.T.; Deshmukh A.R.; Nawale L.U.; Khedkar V.; Sarkar D.; Mane R.A.; New bithiazolyl hydrazones: Novel synthesis, characterization and antitubercular evaluation. Bioorg Med Chem Lett 2017,27(2),288-294","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s00044-016-1756-y","volume":"26","author":"Popio\u0142ekek \u0141","year":"2017","unstructured":"Popio\u0142ekek \u0141; Hydrazide-hydrazones as potential antimicrobial agents: Overview of the literature since 2010. Med Chem Res 2017,26(2),287-301","journal-title":"Med Chem Res"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1016\/j.bmcl.2017.05.032","volume":"27","author":"Zha G.F.","year":"2017","unstructured":"Zha G.F.; Leng J.; Darshini N.; Shubhavathi T.; Vivek H.K.; Asiri A.M.; Marwani H.M.; Rakesh K.P.; Mallesha N.; Qin H.L.; Synthesis, SAR and molecular docking studies of benzo[d]thiazole-hydrazones as potential antibacterial and antifungal agents. Bioorg Med Chem Lett 2017,27(14),3148-3155","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s12272-015-0699-z","volume":"39","author":"Alam M.S.","year":"2016","unstructured":"Alam M.S.; Lee D.U.; Synthesis, biological evaluation, drug-likeness, and in silico screening of novel benzylidene-hydrazone analogues as small molecule anticancer agents. Arch Pharm Res 2016,39(2),191-201","journal-title":"Arch Pharm Res"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2174\/1570180814666170710160751","volume":"15","author":"Husain A.","year":"2018","unstructured":"Husain A.; Varshney M.M.; Parcha V.; Ahmad A.; Khan S.A.; Nalidixic acid Schiff bases: Synthesis and biological evaluation. Lett Drug Des Discov 2018,15,103-111","journal-title":"Lett Drug Des Discov"},{"key":"ref=31","first-page":"245","volume":"13","author":"Kalluraya B.","year":"2004","unstructured":"Kalluraya B.; Isloor A.M.; Frank P.V.; Jagadeesha R.L.; Synthesis and pharmacological activity of some-4-(substituted)-2-4-arylhydrazono-3-methyl-5-oxo-2-pyrazolin-1-yl] thiazoles. Ind J Het Chem 2004,13,245-248","journal-title":"Ind J Het Chem"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"4295","DOI":"10.1016\/j.bmc.2011.05.056","volume":"19","author":"de Oliveira K.N.","year":"2011","unstructured":"de Oliveira K.N.; Costa P.; Santin J.R.; Mazzambani L.; B&#xFC;rger C.; Mora C.; Nunes R.J.; de Souza M.M.; Synthesis and antidepressant-like activity evaluation of sulphonamides and sulphonylhydrazones. Bioorg Med Chem 2011,19(14),4295-4306","journal-title":"Bioorg Med Chem"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"5837","DOI":"10.1016\/j.bmc.2007.05.070","volume":"15","author":"Hayakawa M.","year":"2007","unstructured":"Hayakawa M.; Kawaguchi K.; Kaizawa H.; Koizumi T.; Ohishi T.; Yamano M.; Okada M.; Ohta M.; Tsukamoto S.; Raynaud F.I.; Parker P.; Workman P.; Waterfield M.D.; Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110alpha inhibitors. Bioorg Med Chem 2007,15(17),5837-5844","journal-title":"Bioorg Med Chem"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"4400","DOI":"10.3390\/molecules25194400","volume":"25","author":"Al-Salem H.S.","year":"2020","unstructured":"Al-Salem H.S.; Arifuzzaman M.; Alkahtani H.M.; Abdalla A.N.; Issa I.S.; Alqathama A.; Albalawi F.S.; Motiur Rahman A.F.M.; A series of isatin-hydrazones with cytotoxic activity and CDK2 Kinase inhibitory activity: A potential type II ATP competitive inhibitor. Molecules 2020,25(19),4400","journal-title":"Molecules"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1007\/s11094-009-0184-4","volume":"42","author":"Lisina S.V.","year":"2008","unstructured":"Lisina S.V.; Brel A.K.; Mazanova L.S.; Spasov A.A.; Synthesis and antipyretic activity of new salicylic acid derivatives. Pharm Chem J 2008,42,574-576","journal-title":"Pharm Chem J"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"4104","DOI":"10.1016\/j.ejmech.2010.05.071","volume":"45","author":"Hassan G.S.","year":"2010","unstructured":"Hassan G.S.; Soliman G.A.; Design, synthesis and anti-ulcerogenic effect of some of furo-salicylic acid derivatives on acetic acid-induced ulcerative colitis. Eur J Med Chem 2010,45(9),4104-4112","journal-title":"Eur J Med Chem"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/j.1747-0285.2007.00621.x","volume":"71","author":"da Silva M.","year":"2008","unstructured":"da Silva M.; Menezes C.M.S.; Ferreira E.I.; Leite C.Q.F.; Sato D.N.; Correia C.C.; Pimenta C.P.; Botelho K.C.A.; Topliss method in the optimization of salicylic Acid derivatives as potential antimycobacterial agents. Chem Biol Drug Des 2008,71(2),167-172","journal-title":"Chem Biol Drug Des"},{"key":"ref=38","first-page":"281","volume":"16","author":"Machado P.","year":"2007","unstructured":"Machado P.; Rosa F.A.; Rossatto M.; da Sant\u2019Anna G.S.; Sauzem P.D.; da Silva R.M.S.; Rubin M.A.; Ferreira J.; Bonacorso H.G.; Zanatta N.; Martins M.A.P.; Synthesis and structure of novel 4,5-dihydro-1H-pyrazoles: Salicylic acid based analgesic agents. ARKIVOC 2007,16,281-297","journal-title":"ARKIVOC"},{"key":"ref=39","first-page":"1453","volume":"48B","author":"Pattan S.R.","year":"2009","unstructured":"Pattan S.R.; Rabara P.; Pattan J.S.; Bukitaga A.A.; Wakale V.S.; Musmade D.S.; Synthesis and evaluation of some novel substituted 1,3,4-oxadiazole and pyrazole derivatives for antitubercular activity. Indian J Chem 2009,48B,1453-1456","journal-title":"Indian J Chem"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"381","DOI":"10.4314\/bcse.v25i3.68590","volume":"25","author":"Shelke V.A.","year":"2011","unstructured":"Shelke V.A.; Jadhav S.M.; Shankarwar S.G.; Munde A.S.; Chondhekar T.K.; Synthesis, characterization, antibacterial and antifungal studies of some transition and rare earth metal complexes of N-benzylidene-2-hydroxybenzohydrazide. Bull Chem Soc Ethiop 2011,25,381-391","journal-title":"Bull Chem Soc Ethiop"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/1-4020-5184-0_12","author":"Chaturvedi R.","year":"2007","unstructured":"Chaturvedi R.; Shah J.; Salicylic acid in plant disease resistanceSalicylic acid A Plant Hormone 2007,335-370","journal-title":"Salicylic acid in plant disease resistanceSalicylic acid A Plant Hormone"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"6855","DOI":"10.1016\/j.bmcl.2009.10.083","volume":"19","author":"Chowdhury M.A.","year":"2009","unstructured":"Chowdhury M.A.; Abdellatif K.R.A.; Dong Y.; Das D.; Yu G.; Vel&#xE1;zquez C.A.; Suresh M.R.; Knaus E.E.; Synthesis and biological evaluation of salicylic acid and N-acetyl-2-carboxybenzenesulfonamide regioisomers possessing a N-difluoromethyl-1,2-dihydropyrid-2-one pharmacophore: Dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity. Bioorg Med Chem Lett 2009,19(24),6855-6861","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bmc.2016.11.005","volume":"25","author":"Alam M.S.","year":"2017","unstructured":"Alam M.S.; Choi S.U.; Lee D.U.; Synthesis, anticancer, and docking studies of salicyl-hydrazone analogues: A novel series of small potent tropomyosin receptor kinase A inhibitors. Bioorg Med Chem 2017,25(1),389-396","journal-title":"Bioorg Med Chem"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.5012\/bkcs.2012.33.10.3361","volume":"33","author":"Liu L.","year":"2012","unstructured":"Liu L.; Alam M.S.; Lee D.U.; Synthesis, antioxidant activity, fluorescence properties of new europium complexes with 2-hydroxynaphth-1-aldehyde benzoyl hydrazone Schiff base. Bull Korean Chem Soc 2012,33,3361-3367","journal-title":"Bull Korean Chem Soc"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"163","DOI":"10.22146\/ijc.21357","volume":"12","author":"Budiati T.","year":"2012","unstructured":"Budiati T.; Stephanie D.A.; Widjajakusuma E.C.; Rapid solvent-free microwave-assisted synthesis of some N\u2032-benzylidene salicylic acid hydrazides. Indo J Chem 2012,12,163-166","journal-title":"Indo J Chem"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"4695","DOI":"10.1021\/acsomega.8b00003","volume":"3","author":"Singh A.K.","year":"2018","unstructured":"Singh A.K.; Thakur S.; Pani B.; Ebenso E.E.; Quraishi M.A.; Pandey A.K.; 2-Hydroxy-N\u2032-((thiophene-2-yl)methylene)benzohy-drazide: Ultrasound-assisted synthesis and corrosion inhibition study. ACS Omega 2018,3(4),4695-4705","journal-title":"ACS Omega"},{"key":"ref=47","first-page":"o2208","volume":"E64","author":"Zhang Y.X.","year":"2008","unstructured":"Zhang Y.X.; N\u2032-(Furan-2-ylmethylene)-2-hydroxybenzohydrazide. Acta Crystallogr 2008,E64,o2208","journal-title":"Acta Crystallogr"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.1038\/onc.2014.282","volume":"34","author":"Kasinski A.L.","year":"2015","unstructured":"Kasinski A.L.; Kelnar K.; Stahlhut C.; Orellana E.; Zhao J.; Shimer E.; Dysart S.; Chen X.; Bader A.G.; Slack F.J.; A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer. Oncogene 2015,34(27),3547-3555","journal-title":"Oncogene"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1002\/jcc.21256","volume":"30","author":"Morris G.M.","year":"2009","unstructured":"Morris G.M.; Huey R.; Lindstrom W.; Sanner M.F.; Belew R.K.; Goodsell D.S.; Olson A.J.; AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem 2009,30(16),2785-2791","journal-title":"J Comput Chem"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"Trott O.","year":"2010","unstructured":"Trott O.; Olson A.J.; AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 2010,31(2),455-461","journal-title":"J Comput Chem"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1186\/1471-2105-12-S1-S33","volume":"12","author":"Hsu K.C.","year":"2011","unstructured":"Hsu K.C.; Chen Y.F.; Lin S.R.; Yang J.M.; iGEMDOCK: A graphical environment of enhancing GEMDOCK using pharmacological interactions and post-screening analysis. BMC Bioinformatics 2011,12(Suppl. 1),S33","journal-title":"BMC Bioinformatics"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"W357","DOI":"10.1093\/nar\/gkz382","volume":"47","author":"Daina A.","year":"2019","unstructured":"Daina A.; Michielin O.; Zoete V.; SwissTargetPrediction: Updated data and new features for efficient prediction of protein targets of small molecules. Nucleic Acids Res 2019,47(W1),W357-W364","journal-title":"Nucleic Acids Res"},{"key":"ref=53","first-page":"332","volume":"12","author":"Tanoli S.A.","year":"2014","unstructured":"Tanoli S.A.; Tanoli N.U.; Usmani S.; Ferreira A.G.; The exploration of interaction studies of smaller size, mostly ignored yet intrinsically inestimable molecules towards BSA; An example of STD and DOSY NMR. Cent Eur J Chem 2014,12,332-340","journal-title":"Cent Eur J Chem"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1021\/ci200378s","volume":"51","author":"Park H.","year":"2011","unstructured":"Park H.; Chi O.; Kim J.; Hong S.; Identification of novel inhibitors of tropomyosin-related kinase A through the structure-based virtual screening with homology-modeled protein structure. J Chem Inf Model 2011,51(11),2986-2993","journal-title":"J Chem Inf Model"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.jmb.2012.08.002","volume":"423","author":"Bertrand T.","year":"2012","unstructured":"Bertrand T.; Kothe M.; Liu J.; Dupuy A.; Rak A.; Berne P.F.; Davis S.; Gladysheva T.; Valtre C.; Crenne J.Y.; Mathieu M.; The crystal structures of TrkA and TrkB suggest key regions for achieving selective inhibition. J Mol Biol 2012,423(3),439-453","journal-title":"J Mol Biol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1002\/prot.25756","volume":"87","author":"Schwarz D.","year":"2019","unstructured":"Schwarz D.; Merget B.; Deane C.; Fulle S.; Modeling conformational flexibility of kinases in inactive states. Proteins 2019,87(11),943-951","journal-title":"Proteins"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.addr.2016.05.007","volume":"101","author":"Benet L.Z.","year":"2016","unstructured":"Benet L.Z.; Hosey C.M.; Ursu O.; Oprea T.I.; BDDCS, the Rule of 5 and drugability. Adv Drug Deliv Rev 2016,101,89-98","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.copbio.2007.10.005","volume":"18","author":"Zhang M.Q.","year":"2007","unstructured":"Zhang M.Q.; Wilkinson B.; Drug discovery beyond the \u2018rule-of-five\u2019. Curr Opin Biotechnol 2007,18(6),478-488","journal-title":"Curr Opin Biotechnol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1080\/17425255.2021.1865309","volume":"17","author":"Pathania S.","year":"2021","unstructured":"Pathania S.; Singh P.K.; Analyzing FDA-approved drugs for compliance of pharmacokinetic principles: Should there be a critical screening parameter in drug designing protocols? Expert Opin Drug Metab Toxicol 2021,17(4),351-354","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ijpharm.2018.01.044","volume":"540","author":"Bergstr&#xF6;m C.A.S.","year":"2018","unstructured":"Bergstr&#xF6;m C.A.S.; Larsson P.; Computational prediction of drug solubility in water-based systems: Qualitative and quantitative approaches used in the current drug discovery and development setting. Int J Pharm 2018,540(1-2),185-193","journal-title":"Int J Pharm"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ddtec.2004.11.007","volume":"1","author":"Lipinski C.A.","year":"2004","unstructured":"Lipinski C.A.; Lead- and drug-like compounds: The rule-of-five revolution. Drug Discov Today Technol 2004,1(4),337-341","journal-title":"Drug Discov Today Technol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13020-020-00407-w","volume":"15","author":"Feng Z.","year":"2020","unstructured":"Feng Z.; Cao J.; Zhang Q.; Lin L.; The drug likeness analysis of anti-inflammatory clerodane diterpenoids. Chin Med 2020,15(1),126","journal-title":"Chin Med"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1007\/s00044-013-0861-4","volume":"23","author":"Deb P.K.","year":"2014","unstructured":"Deb P.K.; Kaur R.; Chandrasekaran B.; Bala M.; Gill D.; Kaki V.R.; Akkinepalli R.R.; Mailavaram R.; Synthesis, anti-inflammatory evaluation, and docking studies of some new thiazole derivatives. Med Chem Res 2014,23,2780-2792","journal-title":"Med Chem Res"},{"key":"ref=64","first-page":"263","volume":"4","author":"McDonnell A.M.","year":"2013","unstructured":"McDonnell A.M.; Dang C.H.; Basic review of the cytochrome p450 system. J Adv Pract Oncol 2013,4(4),263-268","journal-title":"J Adv Pract Oncol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1039\/C8MD00472B","volume":"10","author":"Guan L.","year":"2018","unstructured":"Guan L.; Yang H.; Cai Y.; Sun L.; Di P.; Li W.; Liu G.; Tang Y.; ADMET-score - a comprehensive scoring function for evaluation of chemical drug-likeness. MedChemComm 2018,10(1),148-157","journal-title":"MedChemComm"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nature11159","volume":"486","author":"Lounkine E.","year":"2012","unstructured":"Lounkine E.; Keiser M.J.; Whitebread S.; Mikhailov D.; Hamon J.; Jenkins J.L.; Lavan P.; Weber E.; Doak A.K.; C&#xF4;t&#xE9; S.; Shoichet B.K.; Urban L.; Large-scale prediction and testing of drug activity on side-effect targets. Nature 2012,486(7403),361-367","journal-title":"Nature"}],"container-title":["Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573406418666220427105041","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/204122\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573406418666220427105041","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T19:44:56Z","timestamp":1700509496000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/204122\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":66,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573406418666220427105041","relation":{},"ISSN":["1573-4064"],"issn-type":[{"value":"1573-4064","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-12-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-19","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}